215 related articles for article (PubMed ID: 18452850)
1. Studies of prostate-cancer mortality: caution advised.
Etzioni R; Feuer E
Lancet Oncol; 2008 May; 9(5):407-9. PubMed ID: 18452850
[No Abstract] [Full Text] [Related]
2. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
3. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
4. Prostate cancer: numbers may not tell the whole story.
Reynolds T
J Natl Cancer Inst; 2000 Dec; 92(23):1873-6. PubMed ID: 11106674
[No Abstract] [Full Text] [Related]
5. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
6. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
[TBL] [Abstract][Full Text] [Related]
7. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen and prostate cancer prognosis.
Church TR
J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
[No Abstract] [Full Text] [Related]
9. [Detection of prostate cancer: yes or no?].
Van Cangh PJ
Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
[No Abstract] [Full Text] [Related]
10. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
11. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
12. Screening for prostate cancer - will we ever know?
Adolfsson J
Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
[No Abstract] [Full Text] [Related]
13. A population model of prostate cancer incidence.
Tsodikov A; Szabo A; Wegelin J
Stat Med; 2006 Aug; 25(16):2846-66. PubMed ID: 16397859
[TBL] [Abstract][Full Text] [Related]
14. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
15. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer in the serum prostate-specific antigen era.
Humphrey PA
Mayo Clin Proc; 1998 May; 73(5):489-90. PubMed ID: 9581595
[No Abstract] [Full Text] [Related]
17. Latest UK figures show increase in prostate cancer diagnoses and falling death rate.
Mayor S
BMJ; 2012 May; 344():e3252. PubMed ID: 22569872
[No Abstract] [Full Text] [Related]
18. Simulated screening for prostate cancer: the useful model.
Church TR
J Natl Cancer Inst; 2003 Jun; 95(12):838-9. PubMed ID: 12813160
[No Abstract] [Full Text] [Related]
19. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
20. The science and art of prostate cancer screening.
Yao SL; Lu-Yao GL
J Natl Cancer Inst; 2011 Mar; 103(6):450-1. PubMed ID: 21350220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
